Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Europe United Kingdom

Financings Of The Fortnight Ponders A Post-Euro Financing Environment

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Plus news on recent financings by TopiVert, Dendreon, Inhibitex and Celsion.

You may also be interested in...



Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition

In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.

Celsion Transitioning From Development To Commercial-Stage Company; Relocates To N.J.

Biotech's primary liver cancer drug ThermoDox should produce pivotal Phase III data in the next 12 to 14 months.

Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen

Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Europe United Kingdom
UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By